AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
06 Septembre 2022 - 1:30PM
AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or
the “Company”), an immuno-pharma company focused on the research
and development of therapeutics to treat multiple types of cancers,
immune disorders, and viral diseases, including COVID-19, the
disease caused by the SARS-CoV-2 virus, today announced Chris
McAleer, Ph.D., Deputy Chief Science Officer of AIM, and William
Mitchell, M.D. Ph.D., Chairman of the Board of Directors of AIM,
will present at the 2nd Annual Marie Sklodowska-Curie Symposium on
Cancer Research and Care being held at the Roswell Park
Comprehensive Cancer Center in Buffalo, N.Y., September 8-10, 2022.
In addition to management’s presentations, the Company is proud to
announce its sponsorship of the event.
Presentation Details:
Title: Rintatolimod
(Ampligen®): An Investigational Immunomodulatory Agent Targeted at
Cancers of High Unmet NeedAuthor: Christopher
McAleer, Ph.D.Date: Saturday, September 10
Title: The Mechanism of PAMP
Restricted Rintatolimod in Limiting Systemic Inflammatory
ResponsesAuthor: William M. Mitchell, M.D.,
Ph.D.Date: Saturday, September 10
Presentations will take place at the Cancer
Genetics & Pharmacology Building at the Roswell Park
Comprehensive Center.
For more information about the conference,
visit: https://www.roswellpark.org/msc-symposium.
The presentations will be available on the AIM
website once presented at the conference.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders, and viral diseases,
including COVID-19. The Company’s lead product,
Ampligen® (rintatolimod) is an immuno-modulator with broad
spectrum activity being developed for globally important cancers,
viral diseases and disorders of the immune system.For more
information, please visit aimimmuno.com and connect with the
Company on Twitter, LinkedIn, and Facebook.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
AIM ImmunoTech (AMEX:AIM)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024